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Abstract
Background: At present there is no consensus on irradiation treatment volumes for intermediate to high-risk
primary cancers or recurrent disease. Conventional imaging modalities, such as CT, MRI and transrectal ultrasound,
are considered suboptimal for treatment decisions. Choline-PET/CT might be considered as the imaging modality
in radiooncology to select and delineate clinical target volumes extending the prostate gland or prostate fossa. In
conjunction with intensity modulated radiotherapy (IMRT) and imaged guided radiotherapy (IGRT), it might offer
the opportunity of dose escalation to selected sites while avoiding unnecessary irradiation of healthy tissues.
Methods: Twenty-six patients with primary (n = 7) or recurrent (n = 19) prostate cancer received Choline-PET/CT
planned 3D conformal or intensity modulated radiotherapy. The median age of the patients was 65 yrs (range 45
to 78 yrs). PET/CT-scans with F18-fluoroethylcholine (FEC) were performed on a combined PET/CT-scanner
equipped for radiation therapy planning.
The majority of patients had intermediate to high risk prostate cancer. All patients received 3D conformal or
intensity modulated and imaged guided radiotherapy with megavoltage cone beam CT. The median dose to
primary tumours was 75.6 Gy and to FEC-positive recurrent lymph nodal sites 66,6 Gy. The median follow-up time
was 28.8 months.
Results: The mean SUVmax in primary cancer was 5,97 in the prostate gland and 3,2 in pelvic lymph nodes.
Patients with recurrent cancer had a mean SUVmax of 4,38. Two patients had negative PET/CT scans. At 28 months
the overall survival rate is 94%. Biochemical relapse free survival is 83% for primary cancer and 49% for recurrent
tumours. Distant disease free survival is 100% and 75% for primary and recurrent cancer, respectively. Acute normal
tissue toxicity was mild in 85% and moderate (grade 2) in 15%. No or mild late side effects were observed in the
majority of patients (84%). One patient had a severe bladder shrinkage (grade 4) after a previous treatment with
TUR of the prostate and seed implantation.
Conclusions: FEC-PET/CT planning could be helpful in dose escalation to lymph nodal sites of prostate cancer.
Background
In primary and recurrent prostate cancer, the diagnostic
accuracy of conventional imaging modalities, such as
transrectal ultrasound, computed tomography (CT) and
magnetic resonance (MR) imaging, is still considered
suboptimal in the management of these patients [1]. A
substantial number of patients fail within 10 years after
either radical prostatectomy or radiotherapy and precise
information about the site of recurrence is crucial for
the choice of an adequate therapeutic strategy [2]. At
present there is no consensus on irradiation treatment
volumes of intermediate to high-risk primary cancers or
recurrent disease. In recurrent cancer, most frequently
the prostatic fossa with or without the seminal vesicles
but not pelvic lymph nodes have been recommended as
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CT in radiooncology are (1) patient selection for treat-
ment and (2) target volume selection and delineation,
because PET/CT with radiolabelled choline (C11-cho-
line, F18-fluoroethylcholine, F18-fluoromethycholine)
presents high values of sensitivity and specificity in
visualizing sites of disease especially at the lymph nodal
level [5,6], though, its value in primary cancer is a mat-
ter of debate. Thus, Choline-PET/CT might be consid-
ered as the imaging modality in radiooncology to select
and delineate clinical target volumes extending the pros-
tate gland or prostate fossa (with seminal vesicles) [2].
In conjunction with high-precision radiation therapy
techniques, i.e., intensity modulated radiotherapy
(IMRT) and imaged guided radiotherapy (IGRT), it
might offer the opportunity of dose escalation to
selected sites and better tumour control while avoiding
unnecessary inclusion of normal healthy tissues.
Here we report on prostate cancer patients with inter-
mediate to high-risk primary or recurrent disease, who
underwent Choline-PET/CT planned 3D conformal or
IMRT and IGRT radiotherapy with dose escalation to
PET/CT-positive disease sites.
Methods
Patients
Between November 2006 and July 2010, twenty-six
patients received F18-fluorethylcholine-PET/CT as
part of the staging procedure and for radiation ther-
apy treatment planning. Nineteen patients presented
with a recurrent prostate cancer (biochemical relapse)
after previous radical prostatectomy with or without
lymphadenectomy of which one patient presented
with PET/CT positive lymph nodes (iliac and paraaor-
tal) within two years. Seven patients had primary
disease.
Details of patient and tumour characteristics are given
in Table 1. The median age of the patients was 65 yrs
(range 45 to 78 yrs). The majority of recurrent prostate
cancer patients had intermediate to high risk cancer
with 10/19 with initial pT3/4 disease and Gleason score
of 7 or higher (13/19). The primary tumours were cT3
in 5/7 and Gleason score 7 or higher in 5/6 (1: not
available). The median iPSA was 10,4 ng/ml (range: 2,5
to 731) in primary cancer and 12,1 ng/ml (range: 3,35 to
43) in recurrent cancer. The median PSA at time of
FEC-PET/CT in primary cancer was 10,4 ng/ml (range
0,2 to 115) and 1,9 ng/ml (range 0,42 to 65) in recurrent
disease.
Previous therapy of recurrent cancer was radical pros-
tatectomy with or without lymphadenectomy in 16/19.
Two patients had transurethral resection with seed
implantation or antihormonal therapy; one had
radiotherapy of the prostate gland only. In primary can-
cer, 5/7 were treated with neoadjuvant and/or adjuvant
antihormonal therapy.
Imaging
Staging included physical examination with digital rectal
palpation, complete laboratory tests, FEC-PET/CT, and
MRI with endorectal coil (routinely used since 2007).
No bone scintigraphy was required.
PET/CT studies were performed on a combined PET/
CT scanner (Siemens Biograph 16) with radiation ther-
apy equipment (Siemens Medical Solutions, Erlangen,
Germany). All patients fasted for at least 4 hours before
the 18F-fluoroeythylcholine (FEC) PET study. After FEC
injection (350 - 500 MBq; 5 MBq/kg), a dual-time-point
PET/CT scan was carried out in all patients. Early
acquisition including the pelvis and lower abdomen
started 2 minutes after tracer injection, before the tracer
normally reaches the bladder. To significantly reduce
bladder activity in the delayed scan, patients received 20
mg furosemide and were instructed to drink 1-1,5l of
water for forced diuresis. After bladder voiding late
scans started 60-90 minutes post injection. Imaging was
done from skull base to the upper thigh. Static 3D PET
data were acquired at 3 minutes per bed position. No
dynamic acquisition was performed. Standard uptake
values (SUV) are reported as SUVmax values. Region of
interest (ROI) were ellipsoid volumes of interest with
appropriate dimensions to only include the interesting
structure.
The acquisition protocol included a full diagnostic CT
scan native and with i.v. contrast. In addition to stan-
d a r d5m ms l i c et h i c k n e s s ,2m ms l i c e sw i t h1m m
increments were reconstructed (2D OSEM iterative
reconstruction algorithm) for diagnostic purposes and
multi-planar-reformation.
PET/CT interpretation was performed by an experi-
enced nuclear medicine physician/radiologist (AW). A
multimodality computer platform (TrueD - Syngo Mul-
timodality Workplace, Siemens Medical Solutions,
Erlangen, Germany) was used for image review and
interpretation.
Visual assessment of focal increased tracer uptake
higher than the surrounding background was used as a
criterion for malignancy. High focal uptake in the pros-
tate and prostate region was considered to be primary
tumor/recurrent disease. Focal increased uptake in the
pelvic and retroperitoneal lymph nodes or in the skele-
ton were interpreted as metastatic disease. Mild tracer
uptake in distal iliacal and inguinal lymph nodes
occurred regularly and was considered as reactive. Care
was taken to differentiate physiologic high choline
uptake from sites with pathologic uptake.
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Treatment planning was done with Masterplan (Nucle-
tron, The Netherlands) in case of 3D-conformal techni-
que and KonRad or Prowess Panther DAO in case of
IMRT planning. Patients were treated five times weekly
with 1,8 (2,0) Gy/fraction up to a median dose of 75,6
Gy (range: 72 - 75.6 Gy) in primary cancer and 66,6 Gy
(range 55.8 to 75.6 Gy) in recurrent disease. In low risk
patients with primary disease, only the prostate gland
without seminal vesicles were included in the clinical
target volume. In intermediate and high risk patients
with primary disease, the prostate gland and seminal
vesicles were included up to a maximum dose of 66,6
Gy. In case of involvement of the seminal vesicles, the
involved part of the seminal vesicle was carried to the
maximum dose of 75,6 Gy. The planning target volume
( P T V )i n c l u d e dt h eC T Vp l u s8- 1 0m ms a f e t ym a r g i n s
lateral, longitudinal and ventral, and 5 to 8 mm dorsal
for a maximum dose of 70,2 Gy, or 3 - 5 mm dorsal
from 70,2 to 75,6 Gy.
Pelvic lymph nodes were treated in case of FEC-PET/
CT positive lymph nodes or a risk of lymph node invol-
vement greater 20% according to The Artificial Neural
Networks in Prostate Cancer Project (ANNs in CaP;
http://www.prostatecalculator.org). In case of pelvic
lymph node irradiation, all pelvic lymph nodes up to the
level of L5/S1 were irradiated with a total dose of 45 Gy
in 3D conformal irradiation or 50,4 Gy in IMRT with a
boost to the FEC-PET/CT positive lymph nodes. In
recurrent cancer, the dose to the prostatic bed was 60
Gy from 2006 to 2008 and thereafter 64 to 66,6 Gy. If a
FEC PT/CT positive foci was detected in the prostatic
bed, a boost dose was given up to 70,2 Gy or 75,6 Gy in
one case of a large macroscopic nodule. Volumes of
Table 1 Patient and tumor characteristics
Pt. Age (yr) stage Gleason iPSA PSA nadir dt PSA
(mo.)
PSA before FEC PET/CT Previous therpay
1 73 cT2 cN0 7 11,5 - 3 11,5 pos. (P) -
2 59 cT2 cN0 6 9,1 - 7 9,1 pos. (P) -
3 64 cT3 cN0 n.a. 731 - n.a. 36 pos. (P, Bo., Bl) AHT
4 77 cT3a cN0 7 3,4 - n.a. 3,4 pos. (P) AHT
5 71 cT3b cN0 8 2,5 - n.a. 2,5 pos. (P, Ln) AHT
6 77 cT3b cN0 7 10,4 - n.a. 10,4 pos. (P) AHT
7 74 cT3b cN0 7 27,5 - n.a. 0,2 pos. (P) AHT
8 60 cT2 cN0 7 13 - 3 13 pos. (Ln) TUR-P, Seed
9 65 cT2 cN0 9 26,9 n.a. n.a. - pos. (lLn) RT P
10 63 pT1c cN0 6 4,71 3,49 n.a. 2,2 pos. (P) RP, AHT
11 67 pT2a cN0 7 4,78 0,69 3 1,92 pos. (Ln) RP
12 58 pT2b pN0 7 8,24 < 0,04 1 0,51 pos. (Ln) RP, LAD
13 68 pT2c pN0 9 12,1 0,23 7 0,48 pos. (P, Ln) RP, LAD
14 66 pT2c cN0 5 3,35 0,1 10 2,21 pos. (Ln) RP, LAD
15 65 pT2c cNx 7 7,45 0,13 <3 1,19 pos. (P, Ln) RP, AHT
16 71 pT3a cN0 10 n.a. n.a. n.a. 6,5 pos. (P, Ln) TUR-P, AHT
17 71 pT3a pN1 7 n.a. n.a. n.a. 4,8 pos. (Ln) RP, LAD, AHT
18 71 pT3a pN0 5 7,76 0,03 6 1,25 pos. (P, Ln) RP, LAD, RT P
19 69 pT3a cN0 7 15,4 0,18 6 0,65 neg. RP
20 71 pT3a pN0 6 n.a. 0,38 > 12 0,75 neg. RP, LAD
21 65 pT3b pN1 7 14 0,89 4 1,69 pos. (Ln) RP, LAD, AHT
22 70 pT3b pN0 7 43 0,62 3 1,89 pos. (P, Ln) RP, LAD, AHT
23 69 pT3b pN0 7 14,3 0,17 2,5 0,42 pos. (Ln) RP, LAD
24 55 pT3b pN0 6 15 0,35 n..a. 1,2 pos. (Ln) RP, LAD
25 68 pT4 pN0 7 n.a. n.a. 6,3 3 pos. (P, bone) RP, LAD, AHT
26 74 pT3a pN0 5 7,76 0,03 < 3 2,87 pos. (Ln) RP, LAD, RT P+Ln
Abbreviation: stage: initial tumor stage; iPSA: initial PSA value (ng/ml); PSA nadir: minimal PSA value after prostatectomy (ng/ml); dt PSA: PSA doubling in
months; PET/CT: FEC-PET/CT result (P: FEC uptake in prostate gland or prostate bed; Ln: FEC uptake in lymph nodes; Bo: FEC uptake in bone; Bl: FEC uptake in
bladder).
Previous therapy: Therapeutic modalities before PET/CT-planned irradiation. RT: radiotherapy (P: prostate; Ln: pelvic lymph nodes); AHT: anti-hormonal therapy;
RP: radical prostatectomy; LAD: pelvic lymphadenectomy. n.a.: not available.
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a recurrence in seminal vesicles. The dose to 20% of the
rectum (V20) was kept to a maximum of 70 Gy. Weekly
portal imaging was done in the case of 3D conformal
irradiation or with megavoltage cone beam CT (CBCT)
in the case of IMRT, with daily CBCT’s during the first
week and thereafter once weekly.
Linear accelerators with 6 and 10 MV photons were
used equipped with electronic portal imaging (Siemens
Oncor) or Megavoltage Cone Beam CT (Siemens
Artiste).
Follow up
Clinical outcome was determined from regular follow-
up visits 6 to 8 weeks after the end of radiotherapy and
thereafter every six to twelve months and/or a question-
naire or telephone consultations of urologists assigned
with the primary care of the patients. The median follow
up time was 28 months.
Statistical analysis
Outcomes were defined from the start of irradiation.
Kaplan-Meier curves were used to estimate overall, bio-
chemical relapse free and distant disease free survival.
R-square given is a correlation coeefficient. All statistical
analyses were done with GraphPad Prism (version 5.0c;
GraphPad Software Inc.).
Results
FEC-PET/CT
The PET/CT-studies were positive in 24/26 cases. In
primary cancer, one patient had bone metastases and
bladder infiltration, and one had FEC-uptake in the
prostate gland and pelvic lymph nodes. In Figure 1,
maximum standardized uptake values (SUVmax)a r e
shown. The mean SUVmax in primary cancer was 5,97
(range: 3.8 to 8.2) in the prostate gland and 3,2 in pelvic
lymph nodes. Patients with recurrent cancer had a mean
SUVmax of 4,38 (range: 1,6 to 15,3). Two patients had
negative PET/CT scans. Both had PSA values at time of
FEC-PET/CT below 1 ng/ml (0,65 and 0,75 ng/ml). FEC
uptake was found in recurrent tumours in the prostatic
bed in 4 cases. FEC uptake in pelvic lymph nodes was
found in the majority of cases in external iliac nodes (7/
20; 35%), within the fossa obturatoria (4/20; 20%), and
common iliac nodes (3/20; 15%). Two cases with presa-
cral nodes were found. On contrast-enhanced CT the
foci correlated with lymph nodes.
The median PSA at the time of PET/CT was 10.4 ng/
ml(range: 0.2 to 115 ng/ml) for primary cancer and 1.9
ng/ml (range: 0.42 to 65 ng/ml) in recurrent cancer.
No correlation was found between PSA at the time of
PET/CT and SUVmax of the prostate gland or fossa or
lymph nodes. The R square for combined data of
SUVmax prostate and lymph nodes was 0,02224 (p =
0.45), as shown in Figure 2.
Survival
Overall survival of all PET/CT-planned patients is
depicted in Figure 3. At 28 months (median follow up
time), the survival rate is 94%. In Figure 4, the biochem-
ical relapse free survival (BRFS) is given. For primary
tumours, the BRFS is 83% at 28 months, whereas, it is
49% for recurrent tumours. The median survival time
for recurrent tumours is 28.3 months and not reached
for primary cancer. In Figure 5 the distant disease free
Figure 1 SUVmax for primary and recurrent prostate cancer. The
maximum standardized uptake value (SUVmax) is given for primary
and recurrent prostate cancer receiving a Choline-PET/CT for
diagnosis and radiotherapy treatment planning. The mean SUVmax
for primary and recurrent cancer are shown. The difference is not
significant (p = 0.089).
Figure 2 SUVmax and PSA. The maximum standardized uptake
value (SUVmax) is shown as a function of PSA values (ng/ml) at the
time of FEC-PET/CT scanning. Open symbols denote SUVmax values
of lymph nodes, closed squares those of the prostatic gland or
fossa. No correlation was found (R
2 for combined data of prostate
and lymph nodes was 0,02224; p = 0.45).
Würschmidt et al. Radiation Oncology 2011, 6:44
http://www.ro-journal.com/content/6/1/44
Page 4 of 8survival (DDFS) is shown. Patients with primary
tumours have 100% DDFS rate at 28 months and 75%
for patients with recurrent disease.
An example of the dose distribution of FEC-PET/CT-
planned IMRT radiotherapy is given in Figure 6 (patient
number 24, table 1).
Patterns of relapse
A relapse in multiple lymph nodes and bone metastases
occurred in one patient after 15.7 and 41.9 months. In
another patient, a paraaortic lymph node relapse outside
the initial radiotherapy portals was observed 28.3
months after PET/CT-planned radiotherapy. He
declined chemotherapy of his hormone refractory cancer
and chose instead a FEC-PET/CT-planned IMRT of the
paraaortic lymph nodes with dose-escalated boost to the
lymph node metastases.
One patient, who initially had radiotherapy of the
prostate gland and antihormonal therapy, had his first
relapse 3 years later in multiple pelvic and paraaortic
and lymph nodes. As he experienced a further progress
in pelvic lymph nodes he was referred to radiotherapy.
Systemic therapy was difficult because of multiple co-
morbidities. A PET/CT-planned 3D conformal radio-
therapy of the pelvic lymph nodes was performed with
boost to the metastatic lymph node of 60 Gy. Bone
metastases were detected 18.3 months after PET/CT
planned radiotherapy. The patient had an infield, symp-
tomatic pelvic lymph node recurrence 26.8 months after
PET/CT-planned radiotherapy and was offered IMRT
reirradiation to alleviate pain.
Two patients died during the follow-up period. Death
occurred in one patient at 33.3 months because of bone
metastases. Another patient died unexpectedly of
unknown cause and without signs of prostate cancer at
17.5 months.
Toxicity
Acute toxicity was minimal or mild in 22/26 (85%)
patients. Moderate side effects of the rectum or bladder
occurred in 4/26 (15%). No or mild late side effects
were observed in the majority of patients (84%). Two
patients had moderate rectal problems (grade 2, CTC)
and one patient had moderate fatigue. In one patient
symptomatic bone pain requiring analgesics developed
25 months after the end of treatment. Signal alterations
Figure 3 Overall survival. The overall survival rates are shown for
all patients (n = 26). The 2 and 3 year survival rates were 94.4% and
82.6%.
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Figure 4 Biochemical relapse free survival. The biochemical
relapse free survival (BRFS) rates are shown for recurrent (n = 17;
dashed line) and primary prostate cancer (n = 7; blue solid line).
The 2 and 3 year BRFS rates are 83.3% and 83.3% for primary, and
82.5% and 48.9% for recurrent tumours. The median survival time
for recurrent tumors is 28.3 months and not reached for primary
cancers. The difference between primary and recurrent cancers is
not significant (p = 0.6).
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Figure 5 distant disease free survival.T h ed i s t a n td i s e a s ef r e e
survival (DDFS) rates are shown for recurrent (n = 15; blue solid
line) and primary prostate cancer (n = 7; dashed line). The 2 and 3
year DDFS rates are 100% and 75% for primary, and 90% and 75%
for recurrent tumours. The difference between primary and
recurrent cancers is not significant (p = 0.51).
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metastases were found in an MRI. Complete relief could
be achieved within 7 months. No evidence of disease
was found 52.4 months after end of treatment with a
PSA of 0.
One case with a severe grade 4 late effect of the blad-
der was observed. The patient initially had a TUR of the
prostate gland and seed implantation in curative inten-
tion. He experienced a recurrence in a seminal vesicle
and in iliac lymph nodes 54 months after initial treat-
ment. The patient was extensively informed about the
potential risks of reiiradiation after declining alternative
tretament options e.g. docetaxel chemotherapy. Based
on this individual treatment decision, he received PET/
CT-planned IMRT to the prostate gland, seminal vesi-
cles and pelvic lymph nodes of 45 Gy with a boost to
the PET/CT positive seminal vesicle and lymph nodes
of 55.8 Gy at 1.8 Gy per fraction. Severe bladder shrink-
age made a bladder removal necessary with construction
of a transversum conduit 2 years after PET/CT IMRT.
He is alive and without evidence of disease 28.8 months
after PET/CT IMRT.
Discussion
In this single institutional experience, 26 patients with
mainly intermediate to high risk primary or recurrent
prostate cancer received FEC - PET/CT planned radio-
therapy with escalated boost doses to PET/CT positive
lymph node sites. Doses to lymph nodes of up to 66,6
Gy were well tolerated. Local control rates after a med-
ian follow up time of 28 months are encouraging with
only two documented infield recurrences.
F18-fluoroethylcholine/11C-choline have been devel-
oped as imaging probes in PET imaging [7]. It might be
helpful in target volume definition in radiotherapy espe-
cially for irradiation of nodal sites in the absence of reli-
able conventional imaging modalities as MRI and CT.
The accuracy of PET/CT in detecting lymph node
Figure 6 Dose distribution of FEC-PET/CT planned IMRT. An example of F18-fluoroethylcholine PET/CT-planned IMRT is shown (patient
number 24, Table 1). PET/CT- fused images (upper part) showed a single positive lymph node in the right fossa obturatoria with an SUV max of
6,0 and an maximum diameter of 1,6 cm. The patient received IMRT irradiation of the pelvic lymph nodes to 45 Gy (five weekly fractions of 1,8
Gy) with a total boost dose of 66,6 Gy applied to the lymph node metastases (lower part of figure; colour wash images of transversal and
coronal plane are depicted. Green: 42 Gy; red to orange: 60 to 72 Gy).
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assessed in a few studies to date. In one prospective
study [8], 22 of 36 patients had a PSA relapse after cura-
tive treatment for prostate cancer and were re-staged
with 11C- choline PET. Five of these patients (four after
radical prostatectomy, one after radiotherapy) showed
increased uptake of choline in pelvic lymph nodes. After
lymphadenectomy, all five of these patients were found
to have metastatic nodal disease. The same group exam-
ined in a prospective study 67 consecutive patients with
histological proven prostate cancer with 11C-choline
PET [9]. Of these, 43 patients had pelvic lymphadenect-
omy and 15/43 patients had histologically proven lymph
node metastases. 11C-Choline PET was true-positive in
12 patients with uptake of 11C-choline in pelvic lymph
nodes and false-negative in 3 patients. A total of 27
metastatic lymph nodes were identified after pelvic lym-
phadenectomy. 11C-Choline PET identified 19 of 27
(70%) of these metastatic nodes. The sensitivity of 11C-
PET/CT was 80%, the specificity 96%, and accuracy 93%.
It is unclear at which PSA level choline PET/CT
might have an impact on treatment decisions [10,11].
Cimitan et al. [5] studied 100 consecutive patients with
PET/CT because of biochemical relapse of prostate can-
cer. The majority of negative PET/CT scans (41/46)
were observed in patients with a post-treatment serum
PSA <4 ng/ml, and most true positive PET/CT scans
(43/53) were observed in patients with serum PSA >4
ng/ml. They suggested limiting PET/CT to selected
patients with higher PSA levels and/or poorly differen-
tiated prostate carcinoma (Gleason score 7 or higher).
In the current study, both patients with a negative FEC-
PET/CT had PSA values below 1 ng/ml at the time of
PET/CT.
We did not use FEC-PET/CT-directed dose escalation
on intraprostatic lesions. Niyazi et al. [12] employed a
mathematical model assuming various PET detection
rates and alpha-beta values to estimate the effect of
dose escalation on intraprostatic lesions. The model was
based on several fundamental assumptions (uniform clo-
nogenic cell density, no interaction between adjacent
tumor cells, no sub-volume effects and a uniform radio-
sensitivity of all tumor cells). No time factors were con-
sidered. Outcome was highly variable depending on the
inital assumptions. The authors’ conclusions were skep-
tical about the possibilty of achieving clinically meaning-
ful increases in local tumour control rates with this
approach. It is unclear whether this skepticism also
holds true for dose escalation to lymph nodes as was
performed in the current study. The therapeutic benefit
might be higher, because dose escalation is usually
restricted to the prostate gland but not to lymph nodes
due to the inaccuracy of conventional imaging modal-
ities and concerns about bowel toxicity. Thus, total
doses to lymph nodes are generally limited to below 60
Gy. In the current study we could demonstrate that
total doses to metastatic lymph nodes of up to 66,6 Gy
applied with IMRT and IGRT are safe and well toler-
ated. Acute and late toxicity to small bowel was not
increased compared to standard approaches with lower
doses to pelvic lymph nodes. The observed local and
regional control rates are encouraging. Thus, our
patients seemed to benefit from increased locoregional
control rates without increased normal tissue complica-
tion rates.
Though molecular imaging with choline PET/CT is
promising, careful interpretation of PET/CT findings
and consideration of clinical data is necessary in deci-
sion-making. Spatial resolution of the current PET/CT
scanners is still limited to about 5 - 8 mm. In addition,
interpretation of PET/CT data may be difficult in several
circumstances. Examples are a possibly decreased sensi-
tivity of choline-PET in androgen-deprived patients [13]
and inflammatory tissue changes resulting in an
increased uptake of choline imitating cancer growth
[14].
Conclusions
F18-fluoroethylcholine-PET/CT could be helpful in dose
escalation in prostate cancer allowing boost doses > 60
Gy to metastatic lymph nodal regions if PET/CT-
planned intensity modulated and image guided radio-
therapy is used. Thus, there might be still a curative
chance for selected patients with metastatic lymph
nodes or recurrent disease.
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